Glycemic exposure is affected favorably by inhaled human insulin (exubera) as compared with subcutaneous insulin glargine (lantus) in patients with type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 11, Issue 5, 2009, Pages 307-313

  Hompesch, Marcus ^a,d   Kollmeier, Alexa ^a   Rave, Klaus ^b   Heinemann, Lutz ^b   Mitnick, Michael ^c   Davies, Simon ^c   Strack, Thomas ^c  

^a Clinical Research Inc   (United States)

^b Profil Institut fuer Stoffwechselforschung   (Germany)

^c PFIZER INC   (United States)

^d Profil Institute for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; RECOMBINANT HUMAN INSULIN; ROSIGLITAZONE; SULFONYLUREA;

ABNORMAL LABORATORY RESULT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; TREMOR; VITAL SIGN;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; MONITORING, AMBULATORY; RANDOM ALLOCATION;

EID: 66749095295     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0080     Document Type: Article

References (20)

1. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265.
2. Bastyr EJ III, Johnson ME, Trautmann ME, Anderson JH Jr, Vignati L: Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999;21:1703-1714.
3. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
4. Guideline for Management of Postmeal Glucose. Brussels: International Diabetes Federation, 2007.
5. Royle P, Waugh N, McAuley L, McIntyre L, Thomas S: Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2003;CD003890.
6. Patton JS, Bukar JG, Eldon MA: Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmaco-kinet 2004;43:781-801.
7. Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH: Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003;163:2277-2282.
8. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M: An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006;29:1818-1825.
9. DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, Phillips LS: Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005;28:1922-1928.
10. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26:3080-3086.
11. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T: Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28:1077-1082.
12. Hausmann M, Dellweg S, Osborn C, Heinemann L, Buch-wald A, Rosskamp R, Genova P, Heise T: Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study. Diabetes Obes Metab 2006;8:574-580.
13. 1c. Diabetes Care 2003;26:881-885.
14. Home P: Contributions of basal and post-prandial hy-perglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005;21: 989-998.
15. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T: Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999;144:229-235.
16. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000;23:1830-1834.
17. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R, Tuomilehto J: Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002;23: 1267-1275.
18. Edgerton DS, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Sivakumaran S, Strack TR, Cherrington AD: Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 2005; 54:1164-1170.
19. Edgerton DS, Cherrington AD, Williams P, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Kuo MC, Strack TR: Inhalation of human insulin (Exubera) augments the efficiency of muscle glucose uptake in vivo. Diabetes 2006;55:3604-3610.
20. Henderson JN, Allen KV, Deary IJ, Frier BM: Hypoglycae-mia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003;20:1016-1021.